Cogent Biosciences, Inc. (NASDAQ: COGT) is a Healthcare company (Biotechnology) with a market capitalization of $4.8B. The Maz Rating grades it against the other companies in its sector.
Cogent Biosciences, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $27.85, Cogent Biosciences, Inc. trades at 9.3x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -71.1%, return on invested capital of -55.6% and a free cash flow yield of -6.8%. On the balance sheet: a debt-to-equity ratio of 0.47 and a current ratio of 10.99. Over the past 52 weeks the share price ranged from $26.36 to $43.73, with a beta of 0.34.
Cogent Biosciences, Inc. does not currently pay a dividend.
12 Wall Street analyst ratings cover the stock: 10 Buy and 2 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Cogent Biosciences, Inc. (COGT) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 4.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 14.2% / 30% · Interest income / Revenue 705200000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 4.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 14.2% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 705200000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 4.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 14.2% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 705200000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 26.0% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 95.5% / 33.33% · Receivables / Avg Assets (4Q) 0.00% / 33.33% · Interest income / Revenue 705200000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 26.9% / 33.33% · (Cash+ST Inv) / Total Assets 95.1% / 33.33% · (Cash+Recv) / Total Assets 95.1% / 33.33% · Interest income / Revenue 705200000.0% / 5% | Fail |
No. As of September 2026, Cogent Biosciences, Inc. (COGT) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Cogent Biosciences, Inc. is over the AAOIFI limit on Interest income / Revenue.
About 705200000.0% of each dividend: Cogent Biosciences, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.